NASDAQ:KRRO Korro Bio (KRRO) Stock Price, News & Analysis $19.40 -1.54 (-7.33%) As of 01:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Korro Bio Stock (NASDAQ:KRRO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Korro Bio alerts:Sign Up Key Stats Today's Range$19.17▼$22.1550-Day Range$12.83▼$25.6252-Week Range$11.13▼$98.00Volume36,717 shsAverage Volume96,867 shsMarket Capitalization$182.23 millionP/E RatioN/ADividend YieldN/APrice Target$114.63Consensus RatingBuy Company OverviewKorro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Read More… Korro Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreKRRO MarketRank™: Korro Bio scored higher than 32% of companies evaluated by MarketBeat, and ranked 777th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingKorro Bio has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKorro Bio has only been the subject of 4 research reports in the past 90 days.Read more about Korro Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Korro Bio are expected to decrease in the coming year, from ($9.52) to ($10.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Korro Bio is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Korro Bio is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKorro Bio has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Korro Bio's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.16% of the float of Korro Bio has been sold short.Short Interest Ratio / Days to CoverKorro Bio has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in Korro Bio has recently increased by 12.57%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKorro Bio does not currently pay a dividend.Dividend GrowthKorro Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted18.16% of the float of Korro Bio has been sold short.Short Interest Ratio / Days to CoverKorro Bio has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in Korro Bio has recently increased by 12.57%, indicating that investor sentiment is decreasing significantly. News and Social Media3.4 / 5News Sentiment1.06 News SentimentKorro Bio has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Korro Bio this week, compared to 3 articles on an average week.Search Interest1 people have searched for KRRO on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Korro Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.40% of the stock of Korro Bio is held by insiders.Percentage Held by InstitutionsOnly 13.18% of the stock of Korro Bio is held by institutions.Read more about Korro Bio's insider trading history. Receive KRRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Korro Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address KRRO Stock News HeadlinesCantor Fitzgerald Weighs in on Korro Bio FY2025 EarningsMay 2 at 2:41 AM | americanbankingnews.comKorro Bio (NASDAQ:KRRO) Upgraded to "Strong-Buy" at Cantor FitzgeraldMay 1, 2025 | americanbankingnews.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. May 5, 2025 | Golden Portfolio (Ad)Cantor Fitzgerald Initiates Coverage of Korro Bio (KRRO) with Overweight RecommendationApril 30, 2025 | msn.comChardan Capital Initiates a Buy Rating on Korro Bio (KRRO)April 17, 2025 | markets.businessinsider.comKorro Bio initiated with a Buy at ChardanApril 17, 2025 | markets.businessinsider.comChardan Capital Initiates Coverage of Korro Bio (KRRO) with Buy RecommendationApril 17, 2025 | msn.comPiper Sandler Sticks to Their Buy Rating for Korro Bio (KRRO)April 11, 2025 | markets.businessinsider.comSee More Headlines KRRO Stock Analysis - Frequently Asked Questions How have KRRO shares performed this year? Korro Bio's stock was trading at $38.07 at the beginning of 2025. Since then, KRRO shares have decreased by 49.1% and is now trading at $19.3810. View the best growth stocks for 2025 here. How were Korro Bio's earnings last quarter? Korro Bio, Inc. (NASDAQ:KRRO) posted its quarterly earnings data on Tuesday, March, 18th. The company reported ($2.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.33) by $0.07. The company earned $2.27 million during the quarter. Who are Korro Bio's major shareholders? Top institutional shareholders of Korro Bio include Bank of New York Mellon Corp (0.17%) and GAMMA Investing LLC (0.11%). Insiders that own company stock include Venture Opportunity Fund Atlas, David L Lucchino and Vineet Agarwal. View institutional ownership trends. How do I buy shares of Korro Bio? Shares of KRRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Korro Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Korro Bio investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings3/18/2025Today5/05/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRRO Previous SymbolNASDAQ:KRRO CIK1703647 Webwww.frequencytx.com Phone781-315-4600FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Stock Price Target$114.63 High Stock Price Target$180.00 Low Stock Price Target$25.00 Potential Upside/Downside+491.9%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($9.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-50.25% Return on Assets-38.48% Debt Debt-to-Equity RatioN/A Current Ratio11.23 Quick Ratio11.23 Sales & Book Value Annual Sales$2.27 million Price / Sales80.08 Cash FlowN/A Price / Cash FlowN/A Book Value$21.19 per share Price / Book0.91Miscellaneous Outstanding Shares9,391,000Free Float8,862,000Market Cap$181.86 million OptionableNo Data Beta2.66 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:KRRO) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Korro Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Korro Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.